Abstract
Objetive: The study aimed to describe the prevalence and severity of neuropsychiatric symptoms in patients with Alzheimers disease (AD) and vascular dementia (VaD). Patients and methods: We prospectively studied 65 patients with dementia, 37 met the criteria of NINCDS-ADRDA for probable AD and 28 the clinical and radiological criteria of NINDS-AIREN for VaD. Among VaD patients, 22 met the radiological criteria for subcortical VaD. The Minimental State Examination (MMSE) and the Neuropsychiatric Inventory (NPI) were used to evaluate cognitive and neuropsychiatric symptoms. All patients underwent a neuroimaging study (CT scan and/or MRI). Patients were not treated with antidementia or psychotropic drugs. Results: Age, gender, educational level and MMSE scores did not differ between patients (p > 0.05). The total prevalence of neuropsychiatric symptoms was similar in both groups (AD 94.6% vs. VaD 96.4%, p= 0.727). Sleep disturbances (35.1% v 3.6%, p =0.002) and appetite changes (37.8% v 14.3%, p = 0.032) were more prevalent in AD patients than in VaD patients who met the NINDS-AIREN criteria. Sleep disturbances (35.1% v 4.5%, p=0.008), appetite changes (37.8% v 13.6%, p = 0.047) and aberrant motor behaviour (24.3% v 0%, p =0.012) were more prevalent in AD patients than in subcortical VaD. The total scores for sleep disturbance, appetite changes and aberrant motor behavioural were higher in AD patients (p < 0.05). Conclusions: There were no significant differences between AD and VaD patients, except that sleep disturbances, appetite changes and aberrant motor behaviour that were more prevalent and severe in AD.
Keywords: dementia, neuropsychiatric inventory, Alzheimer's disease, vascular dementia, subcortical vascular dementia, NINDS-AIREN criteria, Erkinjuntti criteria
Current Alzheimer Research
Title: Prevalence of Neuropsychiatric Symptoms in Alzheimers Disease and Vascular Dementia
Volume: 5 Issue: 1
Author(s): Manuel Fernandez-Martinez, Jessica Castro, Ana Molano, Juan Jose Zarranz, Rosa Monica Rodrigo and Rafael Ortega
Affiliation:
Keywords: dementia, neuropsychiatric inventory, Alzheimer's disease, vascular dementia, subcortical vascular dementia, NINDS-AIREN criteria, Erkinjuntti criteria
Abstract: Objetive: The study aimed to describe the prevalence and severity of neuropsychiatric symptoms in patients with Alzheimers disease (AD) and vascular dementia (VaD). Patients and methods: We prospectively studied 65 patients with dementia, 37 met the criteria of NINCDS-ADRDA for probable AD and 28 the clinical and radiological criteria of NINDS-AIREN for VaD. Among VaD patients, 22 met the radiological criteria for subcortical VaD. The Minimental State Examination (MMSE) and the Neuropsychiatric Inventory (NPI) were used to evaluate cognitive and neuropsychiatric symptoms. All patients underwent a neuroimaging study (CT scan and/or MRI). Patients were not treated with antidementia or psychotropic drugs. Results: Age, gender, educational level and MMSE scores did not differ between patients (p > 0.05). The total prevalence of neuropsychiatric symptoms was similar in both groups (AD 94.6% vs. VaD 96.4%, p= 0.727). Sleep disturbances (35.1% v 3.6%, p =0.002) and appetite changes (37.8% v 14.3%, p = 0.032) were more prevalent in AD patients than in VaD patients who met the NINDS-AIREN criteria. Sleep disturbances (35.1% v 4.5%, p=0.008), appetite changes (37.8% v 13.6%, p = 0.047) and aberrant motor behaviour (24.3% v 0%, p =0.012) were more prevalent in AD patients than in subcortical VaD. The total scores for sleep disturbance, appetite changes and aberrant motor behavioural were higher in AD patients (p < 0.05). Conclusions: There were no significant differences between AD and VaD patients, except that sleep disturbances, appetite changes and aberrant motor behaviour that were more prevalent and severe in AD.
Export Options
About this article
Cite this article as:
Fernandez-Martinez Manuel, Castro Jessica, Molano Ana, Zarranz Jose Juan, Rodrigo Monica Rosa and Ortega Rafael, Prevalence of Neuropsychiatric Symptoms in Alzheimers Disease and Vascular Dementia, Current Alzheimer Research 2008; 5 (1) . https://dx.doi.org/10.2174/156720508783884585
DOI https://dx.doi.org/10.2174/156720508783884585 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease
Current Pharmaceutical Design The Pro-Apoptotic Substance Thapsigargin Selectively Stimulates Re-Growth of Brain Capillaries
Current Neurovascular Research Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimers and Parkinsons Diseases
Current Pharmaceutical Design Ages of Onset of Mood and Anxiety Disorders in Fragile X Premutation Carriers
Current Psychiatry Reviews Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease
Current Pharmaceutical Design Multifunctional Lipoic Acid Conjugates
Current Medicinal Chemistry Potential Implications of Research on Genetic or Heritable Contributions to Pedophilia for the Objectives of Criminal Law
Recent Advances in DNA & Gene Sequences (Discontinued) Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Neurodegeneration and Neurogenesis: Focus on Alzheimers Disease
Current Alzheimer Research State Dissociation, Human Behavior, and Consciousness
Current Topics in Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Structure-Function Implications in Alzheimers Disease: Effect of Aβ Oligomers at Central Synapses
Current Alzheimer Research Shear Stress-sensitive Carriers for Localized Drug Delivery
Current Pharmaceutical Design Triptan-Induced Torsades de Pointes and Ventricular Fibrillation Cardiac Arrest: Case Report and Review of the Literature
Current Drug Safety Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments
Recent Patents on CNS Drug Discovery (Discontinued) Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets “Tripping out” with the TRP Superfamily and TRPV1 for Novel Neuroprotection
Current Neurovascular Research